FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrea Feyereislova

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Co-author Network

Publications

TOP 3
Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Brian Leyland-Jones; ramon colomer; Maureen E Trudeau; Andrew Wardley; Jean Latreille; David Cameron; Ricardo Cubedo; Nedal Al-Sakaff; Andrea Feyereislova; Olivier Catalani; Yumi Fukushima; Michael Brewster; Javier Cortés
Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.
Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; Sergey Tjulandin; Milvia Zambetti; Federico Vazquez; Mikhail Byakhow; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belén Ojeda; Mauro Mansutti; Alla Bozhok; Roberta Baronio; Andrea Feyereislova; Claire Barton; Pinuccia Valagussa; Jose Baselga
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrea Feyereislova (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet 2010;376(9742):687-97.
2010: Brian Leyland-Jones; ramon colomer; Maureen E Trudeau; Andrew Wardley; Jean Latreille; David Cameron; Ricardo Cubedo; Nedal Al-Sakaff; Andrea Feyereislova; Olivier Catalani; Yumi Fukushima; Michael Brewster; Javier Cortés
Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(6):960-6.
2010: Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; Sergey Tjulandin; Milvia Zambetti; Federico Vazquez; Mikhail Byakhow; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belén Ojeda; Mauro Mansutti; Alla Bozhok; Roberta Baronio; Andrea Feyereislova; Claire Barton; Pinuccia Valagussa; Jose Baselga
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet 2010;375(9712):377-84.
2009: Bella Kaufman; John R Mackey; Michael R Clemens; Poonamalle P Bapsy; Ashok Vaid; Andrew Wardley; Sergei Tjulandin; Michaela Jahn; Michaela Lehle; Andrea Feyereislova; Cédric Révil; Alison Jones
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(33):5529-37.
2008: Eric Van Cutsem; Chris Verslype; P Beale; S Clarke; Roland Bugat; Ashok Rakhit; S H Fettner; Ulrich Brennscheidt; Andrea Feyereislova; Jean-Pierre Delord
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):332-9.
2007: Axel R Hanauske; Jim Cassidy; Javier Sastre; Claus Bolling; Robert J Jones; Ashok Rakhit; Scott Fettner; Ulrich Brennscheidt; Andrea Feyereislova; Eduardo Díaz-Rubio
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):523-31.
2007: Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; José Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez-Rovira; Martine J Piccart-Gebhart
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Lancet 2007;369(9555):29-36.
2003: Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven D Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(12):2237-46.
2003: Patricia M LoRusso; Roy S Herbst; Danny Rischin; Malcolm Ranson; Hilary Calvert; Eric Raymond; Dirk Kieback; Stan Kaye; Luca Gianni; Adrian Harris; Thomas Bjork; Anne-Marie Maddox; Mace L Rothenberg; Eric J Small; Eric H Rubin; Andrea Feyereislova; Anne Heyes; Steven D Averbuch; Judith S Ochs; José Baselga
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2040-8.
2002: José Baselga; Danny Rischin; Malcolm Ranson; H Calvert; E Raymond; D G Kieback; S B Kaye; Luca Gianni; A Harris; T Bjork; Steven D Averbuch; Andrea Feyereislova; Helen Swaisland; Federico Rojo; Joan Albanell
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(21):4292-302.
2002: Malcolm Ranson; Lisa A Hammond; David Ferry; Mark G Kris; Andrew Tullo; Philip I Murray; Vince Miller; Steven D Averbuch; Judith S Ochs; Charles Morris; Andrea Feyereislova; Helen Swaisland; Eric K Rowinsky
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2240-50.
2002: Joan Albanell; Federico Rojo; Steven D Averbuch; Andrea Feyereislova; José Mascaró; Roy Herbst; Patricia M LoRusso; Danny Rischin; Silvia Sauleda; Julia Gee; Robert I Nicholson; José Baselga
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):110-24.